Zhengye Biotechnology Holding Limited (Class A) (ZYBT) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Zhengye Biotechnology Holding Limited (Class A) (NASDAQ: ZYBT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.30 (-9.09% 1D, market cap $67.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZYBT ranks #531 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZYBT carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 20.5%, and ROIC of -22.3%. By comparison, OSTX (OS Therapies Incorporated) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $67.6M) and RNXT (RenovoRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $67.2M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).
Per ZYBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001975641), Zhengye Biotechnology Holding Limited (Class A) generated $16.6M in revenue (-34.8% YoY), -$10.0M in net income, and $1.8M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 10.6% FCF Margin ($1.8M FCF) & 20.5% Gross Margin
20D Institutional Volume Accumulation (±12.5% realized swing band)
Disciplined Float (+0.16% YoY Shares) & executive Form 4 sales trim 13 pts from alignment
While ZYBT currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.48) and Max Pain ($1.37) forces dealer call-delta covering toward $8.41.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Zhengye Biotechnology Holding Limited (Class A) (ZYBT) dropped -9.09% to $1.30, trading at 9% of its 52-week range ($0.62 – $8.01). Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.
The company issued a statement after a sharp increase in trading volume, saying it is unaware of any undisclosed developments that would explain the recent market activity. Key Investor TakeawaysZhengye Biotechnology (NA
Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Jilin, China, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Yahoo Finance coverage on ZYBT stock catalysts, institutional flow, and earnings outlook.
Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5QWEdnZ3VYSGZNRUVROVI2OVVSbVJVVXJjU25sa0toM3FTU0xSQUtSelE4bkkxdHh3UlRfVVhpbldoT1AwRzFPRndhbVFWa3hBUnZGX3FaY3F0dFZfeHpvNW9adXJGSGM3NE9veDNfelktSmZGRGZaTw?oc=5
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNb0k3Q0xPNnV2TVVOd3dfY1NzVEVtRVU3LXVtT3ByNDN6a0xTSms2MDVEWS1XdDg2SFItZFFTaEVzVkdkMWpWRi0xS0ZJQWlDdVhPaGlYZ2prTTBVSGhzcElWU25reGJ0YW43WVNxTWN1cEhwLXhmajMyN2J
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQNHZ5bEYxRy12QVRQN1JUYnYtVGxuVWVmdGFBUTNLVTJYMFZMaDMzM0Vla2dNamZzaUk4dGhHVVFEbTFtRWpRVnJsYWFrT1dvYUNPSEpPUEc5VVRlOTJmaU5KdC1BYUhmbEVKNzY5enJRbVM0VmV6eU51ZDN
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -34.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ZYBT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ZYBT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Zhengye Biotechnology Holding Limited (Class A) (ZYBT) ranks #531 by composite RQD confidence (40/100, grade D-) and #710 by equity capitalization ($67.8M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with ZYBT at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ZYBT
ACTIVE
Zhengye Biotechnology Holding Limited (Class A) | D- | 40/100 | — | 20.5% | -22.3% | -9.09% | $67.8M | Benchmark Subject |
| OSTX OS Therapies Incorporated | D- | 42/100 | — | — | -35.0% | -4.61% | $67.6M | /ostx-vs-zybt → |
| RNXT RenovoRx Inc. | E | 31/100 | — | 70.9% | -35.0% | -10.74% | $67.2M | /rnxt-vs-zybt → |
| FBIO Fortress Biotech Inc. | D- | 39/100 | — | 66.9% | -35.0% | -4.00% | $66.7M | /fbio-vs-zybt → |
| MNOV Medicinova Inc | E | 30/100 | 5.7x | — | -35.0% | 0.00% | $68.9M | /mnov-vs-zybt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zhengye Biotechnology Holding Limited (Class A) (ZYBT) reported GAAP revenue of $16.6M (-34.8% vs. FY2024 revenue of $25.5M ) , GAAP net income of -$10.0M, operating cash flow of $1.9M, and free cash flow of $1.8M (-53.0% YoY). On the balance sheet, ZYBT closed FY2025 with $62.4M in total assets against $0 in total debt (Altman Z-Score: 1.90, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $16.6M | -$10.0M | $1.9M | $1.8M | $62.4M | — |
| FY2024 (FY) | 2024-12-31 | $25.5M | $1.6M | $5.6M | $3.8M | $67.6M | $658.0K |
As of 2026-11-02, Zhengye Biotechnology Holding Limited (Class A) (NASDAQ: ZYBT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.30 (-9.09% 1D, market cap $67.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZYBT ranks #531 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZYBT carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 20.5%, and ROIC of -22.3%. By comparison, OSTX (OS Therapies Incorporated) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $67.6M) and RNXT (RenovoRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $67.2M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).
Per ZYBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001975641), Zhengye Biotechnology Holding Limited (Class A) generated $16.6M in revenue (-34.8% YoY), -$10.0M in net income, and $1.8M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ZYBT last traded at $1.30 (-9.09% on volume of 122,945 shares), positioning the stock -12.16% below its 50-day simple moving average ($1.48) and +12.07% above its 200-day simple moving average ($1.16). Across its 52-week range of $0.62 to $8.01, ZYBT sits at the 9.2% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.14 to $1.46).
Why ZYBT Stock dropped -9.09% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ZYBT scores 40 out of 100, a letter grade of D-, and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
For a prospective investor evaluating the stock today, the rating points to a company with negative operating and net margins, negative ROIC, and a weak forensic profile. The 52-week range of $0.62 to $8.01 and the current price of $1.3 reflect a very wide trading band, and the share price change of -9.09% is consistent with the pressure the rating describes. The upside case rests on the positive FCF yield and the stock's low absolute price, but the source data does not establish a path to earnings or returns that would offset the weaknesses across the pillars.
Per the profile section, Zhengye Biotechnology Holding Limited (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The source data does not describe its products, customers, or revenue model. Per the SEC financials, the company reported revenue of $16.6M for FY 2025 and $25.5M for FY 2024.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $16.6M | $-10.1M | $-10.0M | N/A | $1.8M | N/A | N/A |
| FY 2024 | $25.5M | $2.3M | $1.6M | N/A | $3.8M | $2.5M | $0.7M |
Per the SEC financials, the company moved from positive operating income of $2.3M and net income of $1.6M in FY 2024 to operating and net losses of $-10.1M and $-10.0M in FY 2025, on lower revenue. Per the market data, gross margin is 20.5%, while operating and net margins are both -60%, and ROIC is -22.3%. Per the RQD rating, the Altman Z-Score is 1.9 and the Piotroski F-Score is 4/9. Per the RQD rating, Debt/Equity is 0.5. Per the SEC financials, FY 2025 cash and debt are not available in source data, so current balance sheet posture cannot be fully verified from the filings provided.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the source data.
Real-time company headlines, analyst actions, and sector developments for Zhengye Biotechnology Holding Limited (Class A) (ZYBT) • Click "Debate This Headline" to argue it in the Roar Pit below
The company issued a statement after a sharp increase in trading volume, saying it is unaware of any undisclosed developments that would explain the recent market activity. Key Investor TakeawaysZhengye Biotechnology (NA
Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Jilin, China, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Yahoo Finance coverage on ZYBT stock catalysts, institutional flow, and earnings outlook.
Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5QWEdnZ3VYSGZNRUVROVI2OVVSbVJVVXJjU25sa0toM3FTU0xSQUtSelE4bkkxdHh3UlRfVVhpbldoT1AwRzFPRndhbVFWa3hBUnZGX3FaY3F0dFZfeHpvNW9adXJGSGM3NE9veDNfelktSmZGRGZaTw?oc=5
Welcome to the ZYBT (Zhengye Biotechnology Holding Limited (Class A)) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ZYBT, but look at what you are paying: current EV/EBITDA multiples with 20.5% gross margins. Unless Zhengye Biotechnology Holding Limited (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ZYBT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.30 (52-wk range $0.62 - $8.01), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).